Cargando…

Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China

BACKGROUND: Poor adherence to treatment is a problem in glaucoma, and patient dissatisfaction with topical glaucoma medication is a barrier to adherence. The objective of this study was to evaluate glaucoma patients’ satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution (BTFC)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Xinghuai, Lin, Mingkai, Duan, Xuanchu, Zhang, Chun, Ming, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417666/ https://www.ncbi.nlm.nih.gov/pubmed/28496310 http://dx.doi.org/10.2147/PPA.S131853

Ejemplares similares

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Efficacy and safety of fixed-combination bimatoprost/timolol ophthalmic solution
por: Moon, Suk Bae, et al.
Publicado: (2017)

Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol
por: Fang, Yuan, et al.
Publicado: (2015)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment
por: Brief, Gerrett, et al.
Publicado: (2010)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf, Stefan, et al.
Publicado: (2016)

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects
por: Shim, Seong Hee, et al.
Publicado: (2014)

A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients
por: Jothi, R., et al.
Publicado: (2010)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension
por: Wang, Tao, et al.
Publicado: (2022)

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study
por: Gutierrez-Diaz, Esperanza, et al.
Publicado: (2014)

Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study
por: García-López, Alfonso, et al.
Publicado: (2014)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee, Daniel, et al.
Publicado: (2017)

Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol in Glaucoma and Ocular Hypertension in India: A Multicenter, Open-Label, Phase 3 Study
por: Menon, Meena G, et al.
Publicado: (2022)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
por: Shen, Jie, et al.
Publicado: (2016)

A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure
por: Hartleben, Curt, et al.
Publicado: (2017)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama, Yuko, et al.
Publicado: (2015)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension
por: Pfennigsdorf, Stefan, et al.
Publicado: (2013)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
por: Cai, Ziyan, et al.
Publicado: (2021)

Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients
por: Cordeiro, M Francesca, et al.
Publicado: (2015)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão, Marcelo Lopes da Silva, et al.
Publicado: (2014)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa, Keiji, et al.
Publicado: (2014)

Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma
por: Joshi, Sachin R, et al.
Publicado: (2013)

Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study
por: Bourne, Rupert Richard Alexander, et al.
Publicado: (2019)

Efficacy and Tolerability of Fixed-Combination Brinzolamide/Timolol in Latin American Patients with Open-Angle Glaucoma or Ocular Hypertension Previously on Brimonidine/Timolol Fixed Combination
por: Alezzandrini, Arturo, et al.
Publicado: (2014)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau, Ana, et al.
Publicado: (2013)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
Publicado: (2014)

A patient preference comparison of Azarga(™) (brinzolamide/timolol fixed combination) vs Cosopt(®) (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Mundorf, Thomas K, et al.
Publicado: (2008)

The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies
por: Radcliffe, Nathan M
Publicado: (2014)

Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial
por: Rossetti, Luca, et al.
Publicado: (2015)

Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination
por: Contreras-Salinas, Homero, et al.
Publicado: (2021)

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study
por: Orii, Yusuke, et al.
Publicado: (2022)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
por: Nakamoto, Kenji, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lopuo78mp4js1re9bjgomolq7m